Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study

Abstract

This study aimed to assess the differential effects of first-generation (FGA) and second-generation antipsychotics (SGA) on the prevalence of risk factors for metabolic syndrome among mentally ill patients in Qatar. We also wanted to check if there is proper adherence with the guidelines for prescribing antipsychotics and the monitoring of metabolic effects in this population. We collected the available retrospective data (socio-demographic, psychiatric, anthropometric, and metabolic measures) from the records of 439 patients maintained on antipsychotics. The majority were males, married, employed, having a psychotic disorder, and receiving SGA. Patients on SGA showed more obesity, higher BP, and more elevated triglycerides compared to those on FGA. The prevalence of the abnormal metabolic measures was high in this sample, but those on SGA showed a significantly higher prevalence of abnormal body mass index and BP. Obesity and hypertension were common in patients maintained on antipsychotics, especially those on SGA. Polypharmacy was common, and many metabolic measures were not monitored properly in those maintained on antipsychotics. More prospective studies with guided monitoring of the patients' clinical status and metabolic changes are needed to serve better this population of patients.

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?

“…45 After 3 years of treatment with Aps, the trend of development of MS is gradually increasing, especially, SGAs are more as-sociated with MS rather than FGAs. 46 A recent meta-analysis 45 investigated 126 analyses in 77 publications (n=25,692) regarding the association of APP and MS. According to the results, the overall rate of MS was 32.5%, giving only minor differences in accordance with different methodologies of studies included in the meta-analysis (i.e., criteria of MS definition, treatment setting and sample characteristics).…”

“… 45 After 3 years of treatment with Aps, the trend of development of MS is gradually increasing, especially, SGAs are more associated with MS rather than FGAs. 46 …”

Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders

“…8 Moreover, treatment with psychopharmacological medications, especially certain mood stabilizers and antipsychotics, may cause weight gain and further increase the risk of metabolic disorders. 9,10 In recent years, the importance of a multimorbidity view that brings together the effects of mental and physical health has been increasingly recognized. 11,12 Indeed, recent reviews highlight that abnormal metabolic pathways promote the onset of several SMI, such us SZ, and it is related to increased early morbimortality.…”

Monitoring for the metabolic side effects of second‐generation antipsychotic medications: Psychiatrists' views and practices

“…3 Development of the metabolic syndrome greatly increases risks of the development of diabetes and serious cardiovascular diseases, including stroke, acute myocardial infarction, and renal failure. 4 In addition to the use of SGAs for psychotic symptoms that accompany schizophrenia and bipolar disorder, these agents are increasingly being used to manage other psychiatric conditions including neurodevelopmental disorders, behavioral problems, and anxiety disorders. These off-label uses have resulted in the expansion of the population at risk for metabolic side effects from these drugs.…”

“…The metabolic syndrome results in obesity, hypertension, hyperlipidemia, and insulin resistance thought to be due to an endocrine system dysfunction that may involve alteration in mitochondrial function 3 . Development of the metabolic syndrome greatly increases risks of the development of diabetes and serious cardiovascular diseases, including stroke, acute myocardial infarction, and renal failure 4 …”